Last reviewed · How we verify
NCT05346276
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
trial testing 68Ga-DOTA-hLAG-3 PET/CT in PET/CT in 50 participants. Completed in 13 December 2024.
13 December 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 10 October 2022 |
| Primary completion | 13 December 2024 |
| Estimated completion | 13 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-DOTA-hLAG-3 PET/CT
Conditions studied
Sponsor
The First Affiliated Hospital of Xiamen University
Who can join
Adults 18 to 90, any sex, with PET/CT or hLAG-3. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the potential usefulness of 68Ga-DOTA-hLAG-3 positron emission tomography/computed tomography (PET/CT) for the evaluation of LAG-3 expression in primary and/or metastatic tumors, compared with histopathological results.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor.
Chocarro L, Bocanegra A, Blanco E, Fernández-Rubio L, et al · · 2022 · cited 57× · PMID 35954196 · DOI 10.3390/cells11152351 -
<sup>89</sup>Zr-immuno-PET using the anti-LAG-3 tracer [<sup>89</sup>Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.
Miedema IHC, Huisman MC, Zwezerijnen GJC, Grempler R, et al · · 2023 · cited 29× · PMID 36859619 · DOI 10.1007/s00259-023-06164-w -
Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.
Dobre EG, Surcel M, Constantin C, Ilie MA, et al · · 2023 · cited 22× · PMID 36674595 · DOI 10.3390/ijms24021079
Verify or expand the search:
- PubMed search for NCT05346276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PET/CT
Currently open trials in the same condition.
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07242014 — 68Ga-XACP3 PET/CT in Prostate Cancer · NA · recruiting
- NCT07498933 — FAP-targeted PET/NIR in Lung Malignant Tumors · recruiting
- NCT07151898 — PET/CT for Trop2 ADC Response Evaluation NSCLC · recruiting
- NCT06756334 — Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis · EARLY_PHASE1 · recruiting
Other The First Affiliated Hospital of Xiamen University trials
Trials by the same sponsor.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
- NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
- NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05346276 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05346276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing